Lassen Therapeutics Announces Closing of Oversubscribed $85 Million Series B Financing and Announces First Patient Dosed in the Phase 1 Trial Evaluating LASN01 in Thyroid Eye Disease by Seini Moimoi | Dec 19, 2023 | Portfolio News
Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease by Seini Moimoi | Dec 18, 2023 | Portfolio News
WelbeHealth Opens Bay Area PACE Center Serving Vulnerable Seniors by Seini Moimoi | Dec 13, 2023 | Portfolio News
CG Oncology Receives Both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer by Seini Moimoi | Dec 5, 2023 | Portfolio News
Cretostimogene Grenadenorepvec Monotherapy First Results Show 75.7% Complete Response Rate at Any Time in Patients With High-Risk BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer by Seini Moimoi | Nov 30, 2023 | Portfolio News
